Skip to main content

For the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults

Full Prescribing Information
View Patient Site
Important Safety Information

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

see the acute and preventive efficacy data >

order samples

prescribing Nurtec ODT

search formulary coverage

For U.S. Healthcare Professionals Only

Home

see the acute and preventive efficacy data

order samples

prescribing Nurtec ODT

search formulary coverage

Nurtec ODT

State-specific disclosures

Please select your state for state-specific disclosure information.

Colorado
Vermont (Short)
Vermont (Long)

INDICATIONS

Nurtec ODT is indicated in adults for the:

acute treatment of migraine with or without aura
preventive treatment of episodic migraine

Please click here for full Prescribing Information.

IMPORTANT SAFETY INFORMATIONIMPORTANT SAFETY INFORMATION AND INDICATIONS

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P‑gp.

Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby. Lactation: The transfer of rimegepant into breastmilk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit or call 1‑800‑FDA‑1088.

INDICATIONS

Nurtec ODT is indicated in adults for the:

acute treatment of migraine with or without aura
preventive treatment of episodic migraine

Please click here for full Prescribing Information.

IMPORTANT SAFETY INFORMATIONIMPORTANT SAFETY INFORMATION AND INDICATIONS

Expand

Collapse

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P‑gp.

Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby. Lactation: The transfer of rimegepant into breastmilk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit or call 1‑800‑FDA‑1088.

Home

Follow Us

Contact Us
Privacy Policy
Terms & Conditions

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved. March 2025 PP-NNT-USA-4149

You are about to leave nurtec‑hcp.com

You will now be sent to a website that is not controlled or owned by Pfizer Inc. Pfizer Inc. is not responsible or liable for the website you are about to go to.

Welcome to nurtec‑hcp.com

This website is intended for U.S. healthcare professionals only.

Are you a healthcare professional in the U.S.?

yes

no